
Lexicon Pharmaceuticals, Inc. (LXRX) Stock Ticker
LXRX right now
Market factors today
Unlock the full LXRX picture
About Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
LXRX stock facts
| Ticker symbol | LXRX |
| Exchange | NASDAQ Global Select |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $797.3M |
| CEO | Michael S. Exton |
| Employees | 81 |
| Headquarters | The Woodlands, TX, US |
| IPO date | 2000-04-07 |
| Website | www.lexpharma.com |
What you can see for LXRX on Tickr
Live LXRX price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the LXRX report.
Rankings
FAQ
What is the ticker symbol for Lexicon Pharmaceuticals, Inc.?
The ticker symbol for Lexicon Pharmaceuticals, Inc. is LXRX, listed on the NASDAQ Global Select.
What is LXRX?
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes,…